Peptide News Digest

PCAC Written-Comment Member-Review Deadline Reached Ahead of July 23-24 Vote, NPR Mainstream Feature on Peptide Compounding Push, Rhythm Pharmaceuticals TRANSCEND Setmelanotide (IMCIVREE) Phase 3 in Acquired Hypothalamic Obesity Publishes in the New England Journal of Medicine, HIMS Analyst Ratings Spread From Truist $23 Hold to Canaccord $40 Buy After FDA Peptide Briefing Documents, Oral GLP-1 Tracker Shows Foundayo at 19,879 Scripts in Week 9 Versus Wegovy Pill at 159,000 in Week 22, Vaccinex to Present Pepinemab Glial Biomarker Data at AAIC 2026 in London

PCAC written-comment member-review closes today; NPR feature on peptide push; Rhythm TRANSCEND setmelanotide in NEJM; HIMS analyst spread; oral GLP-1 tracker.

6 stories · Covering regulatory, industry, research, clinical-trials

Editor's Note

Thursday's digest sits two weeks before the July 23-24 PCAC vote, and the day's news arrives in two registers. The procedural side is quiet but load-bearing: the docket's member-review window closes at 11:59 PM ET, and everything the seven panelists read before they walk into White Oak is fixed by end of day. The public-facing side got loud. NPR ran a nationally syndicated feature on the peptide compounding push, with quotes from RFK Jr., ISMP, and independent voices flagging panelist conflicts, moving the panel-composition story past trade press into general-audience awareness. Rhythm Pharmaceuticals put its Phase 3 TRANSCEND setmelanotide (IMCIVREE) data in acquired hypothalamic obesity into the New England Journal of Medicine, keeping the MC4R melanocortin axis on the map alongside Kalohexis's confidential IPO from yesterday. Analyst dispersion around Hims & Hers widened after last week's FDA briefing documents: Truist held at $23 citing peptide-optionality uncertainty, while Canaccord raised to $40 on the branded-drug pivot. On the GLP-1 pill front, Fierce Pharma's Oral GLP-1 Tracker showed Foundayo at 19,879 scripts in week 9, an eight-fold gap behind oral Wegovy at 159,000 in week 22. And Vaccinex previewed pepinemab glial biomarker data for its AAIC 2026 session in London on July 13, keeping the SEMA4D-antibody neurodegeneration story adjacent to the peptide-biologic coverage this site tracks.

Regulatory

PCAC Written-Comment Docket FDA-2025-N-6895 Reaches Member-Review Deadline at 11:59 PM ET on Thursday July 9; Comments Filed by This Cutoff Go Into the Reading Packet Panelists Use to Prepare, Comments After Today Remain on the Record but Reach Members After Initial Review; Absolute Hard Deadline for All Written Submissions Remains 11:59 PM ET on Wednesday July 22 Ahead of the July 23-24 Meeting on BPC-157, KPV, TB-500, MOTS-c, Emideltide/DSIP, Semax, and Epitalon

The FDA Pharmacy Compounding Advisory Committee written-comment docket FDA-2025-N-6895 reaches its member-review cutoff Thursday July 9, 2026 at 11:59 PM ET. Submissions filed by this deadline go into the reading packet PCAC members review ahead of the July 23-24 meeting. Written comments filed after today remain on the public record and inform final agency deliberations but do not reach panelists before their initial preparation. The absolute hard deadline for all written comment submissions is 11:59 PM ET on Wednesday July 22, 2026, one day before the meeting opens at White Oak. The docket has attracted comments from compounding-pharmacy industry groups (Alliance for Pharmacy Compounding, National Community Pharmacists Association, Outsourcing Facilities Association), consumer-safety voices (Public Citizen, Institute for Safe Medication Practices), academic scientists (UC Davis's Paul Knoepfler), and individual physicians and patients on both sides. The FDA career-staff briefing documents released June 29-30 concluded all seven peptides have insufficient evidence for 503A bulks list eligibility, citing immunogenicity, heavy-metal and microbial contamination in compounded samples, mislabeled contents, and thin 503A historical use. The July 9 threshold locks in the reading pile that panelists carry into the July 23 vote.

#pcac #fda #docket #written-comments #bpc-157 #kpv #tb-500 #mots-c #emideltide #semax #epitalon #advisory-committee
Industry

NPR Nationally Syndicated Feature Wednesday July 8: 'What's Behind the Push to Make Peptide Therapies More Readily Available' — RFK Jr. Cited Peptide Benefits on Joe Rogan Earlier This Year, Institute for Safe Medication Practices Warned 'These Peptides Really Do Not Have Established Effectiveness, So the Only Thing You Have Is Risk,' and NPR Reported That Many PCAC Members Have Ties to the Peptide Industry and Work for Clinics That Offer Injectable Peptides

NPR published a nationally syndicated feature Wednesday July 8, 2026 on the FDA effort to expand compounding-pharmacy access to popular peptides including TB-500, BPC-157, and MOTS-c ahead of the July 23-24 PCAC vote. The reporting placed three lines side by side: HHS Secretary Robert F. Kennedy Jr. extolled peptide benefits in a Joe Rogan interview earlier this year and promised to reverse Biden-era restrictions preventing US compounding pharmacies from making them; the Institute for Safe Medication Practices told NPR 'these peptides really do not have established effectiveness, so the only thing you have is risk'; and NPR noted many members of the FDA advisory committee have ties to the peptide industry and work for clinics that offer injectable peptides. The piece syndicated across dozens of member stations (KUAF, NSPR, WLRN, Prairie Public, HPPR, WVXU, KALW, WKNO, KUNC among them), pushing the panel-composition story past trade press (Endpoints, STAT, FiercePharma) and academic-scientist voices (Knoepfler in Washington Post) into general-audience mainstream media two weeks before the vote.

#npr #pcac #rfk-jr #ismp #panelist-conflicts #bpc-157 #tb-500 #mots-c #peptide-compounding #mainstream-media
Research

Rhythm Pharmaceuticals Announces New England Journal of Medicine Publication of Phase 3 TRANSCEND Trial Results for Setmelanotide (IMCIVREE, MC4R Agonist) in Acquired Hypothalamic Obesity on Wednesday July 8: Largest and Longest Placebo-Controlled Study Ever Conducted in the Condition, Reporting Weight and Hunger Improvements in Adults and Pediatric Patients Aged Four and Older Alongside Reductions Documented Against Placebo

Rhythm Pharmaceuticals announced Wednesday July 8, 2026 that Phase 3 TRANSCEND trial results for setmelanotide (IMCIVREE), a melanocortin-4 receptor (MC4R) agonist, in patients with acquired hypothalamic obesity have been published in the New England Journal of Medicine. TRANSCEND is the largest and longest placebo-controlled clinical trial ever conducted in acquired hypothalamic obesity, a rare and severe metabolic condition caused by damage to the hypothalamus from tumors, surgery, radiation, or trauma. The publication documents weight and hunger improvements in adult and pediatric patients aged four years and older across the treatment arm versus placebo control. IMCIVREE is already FDA-approved as a once-daily subcutaneous injection for chronic weight management in adults and pediatric patients aged four and older with acquired hypothalamic obesity, as well as for syndromic or monogenic obesity in patients with confirmed loss-of-function variants. The NEJM publication follows the earlier Kalohexis confidential IPO filing (July 7-8) on the dual MC3R/MC4R melanocortin platform, sustaining momentum around melanocortin biology as the highest-profile non-GLP-1 obesity mechanism in commercial development.

#rhythm-pharmaceuticals #setmelanotide #imcivree #mc4r #melanocortin #acquired-hypothalamic-obesity #nejm #transcend #phase-3
Industry

Hims & Hers Analyst Ratings Spread Widens After FDA PCAC Briefing Documents: Truist Reiterates Hold at $23 Citing Peptide-Optionality Uncertainty, BofA Raises to $36 Neutral, Barclays Raises to $39 Overweight on Novo Nordisk Partnership Improvements, and Canaccord Raises to $40 Buy Citing the Company's Transition From Compounded to Branded Weight-Loss Drugs

Analyst dispersion around Hims & Hers Health (NYSE: HIMS) widened this week following the FDA career-staff briefing documents released June 29-30 concluding all seven PCAC peptides have insufficient evidence for 503A bulks-list inclusion. The four fresh price targets span nearly two-to-one: Truist Securities reiterated a Hold rating with a $23 price target, citing near-term-performance strength tempered by uncertainty around peptide-compounding regulation. BofA Securities raised its price target to $36 from $25 while maintaining Neutral, noting the FDA update is negative for the company's peptide-optionality narrative but not the core weight-loss business. Barclays' Glen Santangelo raised to $39 from $29 while maintaining Overweight, crediting improvements from the renewed Novo Nordisk partnership. Canaccord's Maria Ripps raised to $40 from $32 while maintaining Buy, citing the company's transition from compounded to branded weight-loss drugs. The 74% spread from lowest to highest target reflects analyst disagreement about how much of the Hims growth story now runs through peptide optionality versus branded-GLP-1 rails.

#hims-hers #hims #truist #bofa #barclays #canaccord #analyst-ratings #pcac #peptide-optionality #novo-nordisk
Industry

Fierce Pharma Oral GLP-1 Tracker: Foundayo (Orforglipron) Reaches 19,879 US Prescriptions in Week 9 of Its Launch Compared With 159,000 for Novo Nordisk's Wegovy Pill (Oral Semaglutide 25 mg) at Week 22 — an Eight-Fold Prescription Gap That Spherix Analysis Attributes to Novo's First-Mover Advantage and Brand Familiarity With the Wegovy Name

Fierce Pharma's weekly Oral GLP-1 Tracker, which leverages IQVIA data and analyst notes, reports that Eli Lilly's Foundayo (orforglipron) reached 19,879 US prescriptions in its ninth week of retail launch compared with 159,000 for Novo Nordisk's Wegovy pill (oral semaglutide 25 mg) in its 22nd week. Foundayo received FDA approval April 1, 2026 and began retail shipments through LillyDirect on April 6; the Wegovy pill received FDA approval December 22, 2025 and launched in early January 2026. Adjusting for launch timing, Foundayo tracks numerically behind Wegovy pill at equivalent weeks, though Lilly executives noted on the Q1 earnings call that Foundayo's first-week pace ran ahead of the Zepbound injectable launch (2024). Spherix Global Insights analysis attributes Wegovy pill's uptake advantage to first-mover positioning and physician familiarity with the Wegovy brand name established through the injectable franchise. Foundayo's Q2 sell-in run rate implies roughly $146 million in Q2 revenue and $1.6 billion for full-year 2026 by analyst modeling.

#foundayo #orforglipron #wegovy-pill #oral-semaglutide #oral-glp-1 #fierce-pharma #eli-lilly #novo-nordisk #prescription-tracker #spherix
Clinical Trials

Vaccinex Announces Wednesday July 8 It Will Present New Glial Biomarker Data From the Phase 1/2 SIGNAL-AD Study of Pepinemab (Anti-Semaphorin 4D Humanized IgG4 Monoclonal Antibody) at the Alzheimer's Association International Conference in London on July 13, 2026 Alongside Plans for the Expanded Randomized Phase 2B SIGNAL-AD2 Trial: Elizabeth Evans, PhD (COO/SVP Discovery and Translational Medicine) Will Chair the Featured Research Session

Vaccinex (NASDAQ: VCNX) announced Wednesday July 8, 2026 that it will present new glial biomarker data from the Phase 1/2 SIGNAL-AD study of pepinemab and plans for the expanded Phase 2B SIGNAL-AD2 trial at the Alzheimer's Association International Conference (AAIC) 2026 in London on July 13. Elizabeth Evans, PhD, Chief Operating Officer and Senior VP of Discovery and Translational Medicine, will chair the Featured Research Session. Pepinemab is a humanized IgG4 monoclonal antibody targeting Semaphorin 4D (SEMA4D). The mechanism blocks SEMA4D signaling through astrocyte plexin-B1 receptors, reducing reactive astrocyte activation and downstream neuroinflammation — a disease-modifying approach mechanistically distinct from amyloid- or tau-targeting strategies. Pepinemab is a monoclonal antibody rather than a peptide, but the SEMA4D program sits in the peptide-and-biologic neurodegeneration territory this site tracks alongside the Vera Therapeutics Trutakna (atacicept fusion protein) approval covered yesterday. AAIC readouts to watch: cerebrospinal-fluid glial fibrillary acidic protein (GFAP) and neurofilament light chain (NfL) biomarker shifts on pepinemab treatment.

#vaccinex #pepinemab #sema4d #semaphorin-4d #aaic-2026 #alzheimers-disease #signal-ad #elizabeth-evans #monoclonal-antibody #neurodegeneration